EUCTR2008-004522-16-BE进行中（未招募）1 期
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MULTI-CENTER, MULTI-NATIONAL STUDY FOR EVALUATION OF EFFICACY AND SAFETY OF DU-176B VERSUS WARFARIN IN SUBJECTS WITH ATRIAL FIBRILLATION – Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation (ENGAGE-AF) - ENGAGE AF TIMI-48
Daiichi Sankyo Pharma Development0 个研究点目标入组 20,500 人开始时间: 2008年11月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female subjects with age = 21 years;
- •2. Able to provide written informed consent;
- •3. History of AF documented by any electrical tracing (routine 12-lead electrocardiographic reading [ECG], Holter monitor [continuous ECG recording], rhythm strip, intracardiac electrogram, or pacemaker [PM] or implantable cardiac defibrillator [ICD] interrogation) within the prior 12 months and for which anticoagulation therapy is indicated and planned for the duration of the study; subjects with AF includes subjects with paroxysmal, persistent, or permanent AF and subjects with or without previous VKA (including warfarin) experience (it is anticipated that approximately 40% of subjects will be VKA-naive);
- •4. Subjects must have a CHADS2 index score of = 2. The CHADS2 scoring is performed by assigning 1 point each for a history of congestive heart failure, hypertension, age = 75 years, or diabetes mellitus; and by assigning 2 points for history of stroke or TIA.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 6150
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 14350
排除标准
- •Subjects who meet any of the criteria below will be disqualified from entering the study.
- •1. Transient AF secondary to other reversible disorders (e.g., thyrotoxicosis, cardiac or thoracic surgery, pneumonia, severe anemia);
- •2. Subjects with moderate or severe mitral stenosis, unresected atrial myxoma, or a mechanical heart valve (subjects with bioprosthetic heart valves and/or valve repair can be included);
- •However, subjects with AF and valvular heart diseases such as mitral valve prolapse, mitral valve regurgitation, and aortic valve disease are allowed in the study;
- •3. Subjects with a history of left atrial appendage exclusion (either by surgery or by a procedure);
- •4. Subjects with intracardial mass or left ventricular thrombus;
- •5. Subjects for whom discontinuation of chronic anticoagulation therapy will be considered if a planned pharmacologic, electrical or surgical therapy were to be successful in converting the subject to normal sinus rhythm (NSR) and maintaining that rhythm;
- •6. Subjects with any contraindication for anticoagulant agents;
- •7. Subjects with conditions associated with high risk of bleeding such as past history of intracranial (spontaneous or traumatic), or spontaneous intraocular, spinal, retroperitoneal, or intra-articular bleeding; overt gastrointestinal (GI) bleeding or active ulcer within the previous year; recent severe trauma, major surgery, or deep organ biopsy within the previous 10 days; active infective endocarditis; uncontrolled hypertension (blood pressure [BP] above 170/100 mmHg); or hemorrhagic disorder including known or suspected hereditary or acquired bleeding or coagulation disorder;
- •8. Subjects receiving dual antiplatelet therapy (e.g. aspirin plus thienopryridine such as ticlopidine or clopidogrel) or anticipated to receive such therapy unless all but one of the antiplatelet medications can be safely stopped prior to randomization and while receiving study drug;
- •9. Subjects receiving chronic cyclosporine therapy;
- •10. Subjects receiving prohibited concomitant medications (fibrinolytics, non-study anticoagulants other than those used as a bridge to/from study drug, chronic oral or parental non-aspirin NSAID (use of NSAIDs via other routes are not restricted) use for = 4 days/week, and potent P-gp inhibitors as defined for this study;
- •11. Subjects with acute MI, stroke, acute coronary syndrome (ACS), or percutaneous coronary intervention (PCI) within the previous 30 days;
- •12. Subjects with active liver disease or persistent (confirmed by repeat assessments at least a week apart) elevation of liver enzymes/bilirubin:
- •ALT or AST = 2 times the ULN;
- •TBL =1.5 times the ULN (however, subjects whose elevated TBL is due to known Gilbert's syndrome may be included in the study);
- •13. Subjects with severe renal insufficiency (calculated CrCL <30 mL/min);
- •14. History of testing positive Hepatitis B antigen or Hepatitis C antibody before randomization;
- •15. Any other clinically relevant laboratory abnormality as judged by the Investigator;
- •16. Subjects with a known history of testing positive for human immunodeficiency virus (HIV);
- •17. Subjects with hemoglobin < 10 g/dL or platelet count < 100,000 cells/µL or white blood cell count (WBC) < 3000 cells/µL;
- •18. Subjects with pre-planned invasive procedures (other than routine endoscopy) or surgeries in which bleeding is anticipated during the study period;
- •19. Subjects who received any investigational drug or device within 30 days prio
研究者
相似试验
进行中（未招募）
不适用
ate development study which compares the effectiveness and safety of a not yet approved drug called edoxaban versus a widely-used and approved drug called warfarin in patients with an abnormal heart beat disease called atrial fibrillation. The study is double-blind (that is when neither the patient nor the investigator know which of the 2 drugs the patient is receiving) and is being conducted in many countries around the worldReduction of Stroke and/or systemic embolic event (SEE) in subjects with atrial fibrillation (AF).MedDRA version: 14.1Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersEUCTR2008-004522-16-DKDaiichi Sankyo Pharma Development20,500
进行中（未招募）
不适用
ate development study which compares the effectiveness and safety of a not yet approved drug called edoxaban versus a widely-used and approved drug called warfarin in patients with an abnormal heart beat disease called atrial fibrillation. The study is double-blind (that is when neither the patient nor the investigator know which of the 2 drugs the patient is receiving) and is being conducted in many countries around the worldReduction of Stroke and/or systemic embolic event (SEE) in subjects with atrial fibrillation (AF).MedDRA version: 14.1Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersEUCTR2008-004522-16-DEDaiichi Sankyo Pharma Development20,500
进行中（未招募）
不适用
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MULTI-CENTER, MULTI-NATIONAL STUDY FOR EVALUATION OF EFFICACY AND SAFETY OF DU-176B VERSUS WARFARIN IN SUBJECTS WITH ATRIAL FIBRILLATION – Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation (ENGAGE-AF) - ENGAGE AF TIMI-48Reduction of Stroke and/or systemic embolic event (SEE) in subjects with atrial fibrillation (AF).MedDRA version: 9.1Level: LLTClassification code 10003658Term: Atrial fibrillationEUCTR2008-004522-16-PTDaiichi Sankyo Pharma Development20,500
进行中（未招募）
不适用
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP,MULTI-CENTER, MULTI-NATIONAL STUDY FOR THE EVALUATION OF EFFICACY AND SAFETY OF (LMW) HEPARIN/EDOXABAN VERSUS (LMW) - Evaluation of edoxaban vs. warfarin in subjects with symptomatic venous thromboembolism (VTE)Patients with acute symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism (PE)MedDRA version: 9.1Level: LLTClassification code 10051055MedDRA version: 9.1Level: LLTClassification code 10037377EUCTR2009-014290-40-ITDAIICHI SANKIO DEVELOPMENT LIMITED7,500
进行中（未招募）
1 期
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MULTI-CENTER, MULTI-NATIONAL STUDY FOR EVALUATION OF EFFICACY AND SAFETY OF DU-176B VERSUS WARFARIN IN SUBJECTS WITH ATRIAL FIBRILLATION – Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation (ENGAGE-AF) - ENGAGE AF TIMI-48Prevention of Stroke and/or systemic embolic event (SEE) in subjects with atrial fibrillation (AF).MedDRA version: 9.1Level: LLTClassification code 10003658Term: Atrial fibrillationEUCTR2008-004522-16-SKDaiichi Sankyo Pharma Development20,500